Join
Live feed
·
PRReleasevia Quantisnow
Compugen Ltd. logo

Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

ByQuantisnow·Wall Street's wire, on your screen.
CGEN· Compugen Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CGEN (Compugen Ltd.) and more on Quantisnow.